Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic

Chronic infection with hepatitis C virus (HCV) is estimated to affect approximately 3% of the world's population and cause 350,000 deaths each year. For a number of years, the standard of care has been combination therapy with recombinant alfa interferons—originally as native proteins but more...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen, Henrik, Meyer, Jeff, Freeman, Jeremy, Doyle, Sean E., Klucher, Kevin, Miller, Dennis M., Hausman, Diana, Hillson, Jan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Ltd 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521278/
https://www.ncbi.nlm.nih.gov/pubmed/26357610
http://dx.doi.org/10.14218/JCTH.2013.00014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521278/
https://www.ncbi.nlm.nih.gov/pubmed/26357610
http://dx.doi.org/10.14218/JCTH.2013.00014

Ejemplares similares